Literature DB >> 26617211

Advances in Medical Management of Early Stage and Advanced Breast Cancer: 2015.

Sabrina Witherby1, Tina Rizack2, Bachir J Sakr2, Robert D Legare2, William M Sikov3.   

Abstract

Standard management of early stage and advanced breast cancer has been improved over the past few years by knowledge gained about the biology of the disease, results from a number of eagerly anticipated clinical trials and the development of novel agents that offer our patients options for improved outcomes or reduced toxicity or both. This review highlights recent major developments affecting the systemic therapy of breast cancer, broken down by clinically relevant patient subgroups and disease stage, and briefly discusses some of the ongoing controversies in the treatment of breast cancer and promising therapies on the horizon.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26617211     DOI: 10.1016/j.semradonc.2015.09.005

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  5 in total

1.  GSTP1 c.313A > G mutation is an independent risk factor for neutropenia hematotoxicity induced by anthracycline-/paclitaxel-based chemotherapy in breast cancer patients.

Authors:  Juanzi Zeng; Heming Wu; Donghua Liu; Liang Li; Jiaquan Li; Qiuming Wang; Min Ye; Qingyan Huang; Zhikang Yu; Jinfeng Zhang
Journal:  World J Surg Oncol       Date:  2022-06-22       Impact factor: 3.253

Review 2.  Skin problems and EGFR-tyrosine kinase inhibitor.

Authors:  Toshiyuki Kozuki
Journal:  Jpn J Clin Oncol       Date:  2016-01-29       Impact factor: 3.019

3.  Breast tissue ablation with irreversible electroporation in rabbits: A safety and feasibility study.

Authors:  Wenlong Zhang; Wanning Wang; Wei Chai; Xiaomei Luo; Jiannan Li; Jian Shi; Liqi Bi; Lizhi Niu
Journal:  PLoS One       Date:  2017-07-21       Impact factor: 3.240

4.  CYP2S1 and CYP2W1 expression is associated with patient survival in breast cancer.

Authors:  Radhika Aiyappa-Maudsley; Sarah J Storr; Emad A Rakha; Andrew R Green; Ian O Ellis; Stewart G Martin
Journal:  J Pathol Clin Res       Date:  2022-07-28

5.  Cumulative receiver operating characteristics for analyzing interaction between tissue visfatin and clinicopathologic factors in breast cancer progression.

Authors:  Sin-Hua Moi; Yi-Chen Lee; Li-Yeh Chuang; Shyng-Shiou F Yuan; Fu Ou-Yang; Ming-Feng Hou; Cheng-Hong Yang; Hsueh-Wei Chang
Journal:  Cancer Cell Int       Date:  2018-02-09       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.